Sanofi to acquire VIB-VUB spin-off Ablynx for 3,9 billion Euro
Global biopharmaceutical company Sanofi takes over Ablynx, located in Ghent, for 3,9 billion Euro. In December Ablynx had refused an offer from Novo Nordisk.
The acquisition of Ablynx continues Sanofi’s commitment to breakthrough
innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules.
Different articles appeared in the press.
The story of the discovery of the camelids' antibodies by VUB professors Hamers en Muyldermans, which led to the establishment of Ablynx can be read in De Standaard.